Loading…
SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone
Testosterone levels decline with age. However, until recently well defined harmonised age and/or obesity (BMI
Saved in:
| Published in: | Journal of the Endocrine Society 2020-05, Vol.4 (Supplement_1) |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Journal of the Endocrine Society |
| container_volume | 4 |
| creator | Dewdney, Charlotte Mendoza, Heidi Clark, Rosemary MacRury, Sandra Harvey, Rod Muir, Kenneth Bal, Satinder Dorrian, Catherine Anne Macfarlane, David P |
| description | Testosterone levels decline with age. However, until recently well defined harmonised age and/or obesity (BMI |
| doi_str_mv | 10.1210/jendso/bvaa046.817 |
| format | article |
| fullrecord | <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7208305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_7208305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1427-e1aabac7bada1bd61b57bfc5e117cd751fb6edaf5b2ba960aec45942818c1ff63</originalsourceid><addsrcrecordid>eNpVkdtKAzEQhhdRsNS-gFd5gW2TbHazeyOUUg9QVLRehxwmdUublGRb8R18aFO3iF7NP6dvBv4suyZ4TCjBkzU4E_1EHaTErBrXhJ9lA8o4zUnD6fkffZmNYlxjjElTsIaxQfb1Ol3mmHE0NX7Xtd4hb5F0aLqCVFrvYwcGLSF2PqngHaAXsBDA6aSkWx1zs9cQ-3qQm4g6j-bOeB3aND7btK7VCWnQI3yg5wAxNX5OxeOtv-yr7MImAIxOcZi93c6Xs_t88XT3MJsuck0Y5TkQKZXUXEkjiTIVUSVXVpdACNeGl8SqCoy0paJKNhWWoFnZMFqTWhNrq2KY3fTc3V5twWhwXXpc7EK7leFTeNmK_x3XvouVPwhOcV3gMgFoD9DBxxjA_u4SLI6eiN4TcfJEJE-Kb68xhzs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone</title><source>Oxford University Press Open Access</source><source>PubMed Central</source><creator>Dewdney, Charlotte ; Mendoza, Heidi ; Clark, Rosemary ; MacRury, Sandra ; Harvey, Rod ; Muir, Kenneth ; Bal, Satinder ; Dorrian, Catherine Anne ; Macfarlane, David P</creator><creatorcontrib>Dewdney, Charlotte ; Mendoza, Heidi ; Clark, Rosemary ; MacRury, Sandra ; Harvey, Rod ; Muir, Kenneth ; Bal, Satinder ; Dorrian, Catherine Anne ; Macfarlane, David P</creatorcontrib><description>Testosterone levels decline with age. However, until recently well defined harmonised age and/or obesity (BMI <30kg/m2) adjusted reference ranges did not exist.1 There is also a lack of international consensus on whether an age adjusted reference range (RR) should be used to define the syndrome of hypogonadism in men. Our local referral guideline suggests referral to endocrinology is appropriate if morning testosterone is <9.4nmol/L similar to the Endocrine Society Clinical Practice Guideline.2 In mid 2018 our laboratory adopted the published all men age adjusted RR1. We sought to; i) investigate clinic referrals before and after adoption of the all men age adjusted RR and, ii) to model the impact on referrals and prescription of testosterone replacement therapy (TRT) had we adopted either the lower limit of either all men or non-obese age adjusted RR as our referral criteria. Despite similar numbers of testosterone levels being measured in the laboratory, referrals to endocrine clinic for investigation of male hypogonadism fell by 52% (n=101 vs 48) in the one year following the introduction of the new age adjusted RR, with a corresponding reduction in prescriptions for testosterone. Mean testosterone concentration (6.7±2.5 vs 6.4±3.9nmol/L [mean±SD], NS), and age (51±13.9 vs 50±17.9 years, NS) of individuals referred were similar before and after the change of RR. Of the 101 patients referred for investigation of hypogonadism prior to the new RR mean testosterone concentrations were 8.5±4.5, 7.3±4.1, 6.8±3.6, 6.7±2.1 & 6.6±1.6nmol/L, with 39, 71, 39, 40 & 17% of the 87 patients seen in clinic being prescribed TRT in age groups 19-39 (n=28), 40-49 (n=7), 50-59 (n=33), 60-69 (n=20) &70-79 (n=6) respectively, excluding those with a history of anabolic steroid use or Klinefelter’s syndrome. Mean BMI was 30.9±4.4kg/m2, which was similar between age groups. Had the lower limit of normal of the all men testosterone RR been employed as our referral criteria in the preceding year, 23.8% (24/101) of referrals would not have met referral criteria, and 26.2% (n=11/42) of those receiving a prescription would potentially not have received a trial of TRT. In contrast, had the non-obese age adjusted RR had been adopted for all men 13.9% (14/101) of referrals would not have met referral criteria and, of those prescribed testosterone, 2.4% (n= 1/42) would not have received a trial of TRT. In conclusion, adoption of the all men age adjusted RR for testosterone has been associated with a significant fall in referrals for investigation of male hypogonadism. However, modelling of historical clinic data would suggest that some non-obese individuals miss out on a therapeutic trial of TRT, especially if the all men, rather than non-obese, age adjusted RR is adopted.
Reference: (1) Travison et al, J Clin Endocrinol Metab, 2017,102(4):1161-1173, (2) Bhasin S et al,. J Clin Endocrinol Metab. March 2018;103(5):1715-1744.</description><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvaa046.817</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Reproductive Endocrinology</subject><ispartof>Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)</ispartof><rights>Endocrine Society 2020. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208305/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208305/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Dewdney, Charlotte</creatorcontrib><creatorcontrib>Mendoza, Heidi</creatorcontrib><creatorcontrib>Clark, Rosemary</creatorcontrib><creatorcontrib>MacRury, Sandra</creatorcontrib><creatorcontrib>Harvey, Rod</creatorcontrib><creatorcontrib>Muir, Kenneth</creatorcontrib><creatorcontrib>Bal, Satinder</creatorcontrib><creatorcontrib>Dorrian, Catherine Anne</creatorcontrib><creatorcontrib>Macfarlane, David P</creatorcontrib><title>SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone</title><title>Journal of the Endocrine Society</title><description>Testosterone levels decline with age. However, until recently well defined harmonised age and/or obesity (BMI <30kg/m2) adjusted reference ranges did not exist.1 There is also a lack of international consensus on whether an age adjusted reference range (RR) should be used to define the syndrome of hypogonadism in men. Our local referral guideline suggests referral to endocrinology is appropriate if morning testosterone is <9.4nmol/L similar to the Endocrine Society Clinical Practice Guideline.2 In mid 2018 our laboratory adopted the published all men age adjusted RR1. We sought to; i) investigate clinic referrals before and after adoption of the all men age adjusted RR and, ii) to model the impact on referrals and prescription of testosterone replacement therapy (TRT) had we adopted either the lower limit of either all men or non-obese age adjusted RR as our referral criteria. Despite similar numbers of testosterone levels being measured in the laboratory, referrals to endocrine clinic for investigation of male hypogonadism fell by 52% (n=101 vs 48) in the one year following the introduction of the new age adjusted RR, with a corresponding reduction in prescriptions for testosterone. Mean testosterone concentration (6.7±2.5 vs 6.4±3.9nmol/L [mean±SD], NS), and age (51±13.9 vs 50±17.9 years, NS) of individuals referred were similar before and after the change of RR. Of the 101 patients referred for investigation of hypogonadism prior to the new RR mean testosterone concentrations were 8.5±4.5, 7.3±4.1, 6.8±3.6, 6.7±2.1 & 6.6±1.6nmol/L, with 39, 71, 39, 40 & 17% of the 87 patients seen in clinic being prescribed TRT in age groups 19-39 (n=28), 40-49 (n=7), 50-59 (n=33), 60-69 (n=20) &70-79 (n=6) respectively, excluding those with a history of anabolic steroid use or Klinefelter’s syndrome. Mean BMI was 30.9±4.4kg/m2, which was similar between age groups. Had the lower limit of normal of the all men testosterone RR been employed as our referral criteria in the preceding year, 23.8% (24/101) of referrals would not have met referral criteria, and 26.2% (n=11/42) of those receiving a prescription would potentially not have received a trial of TRT. In contrast, had the non-obese age adjusted RR had been adopted for all men 13.9% (14/101) of referrals would not have met referral criteria and, of those prescribed testosterone, 2.4% (n= 1/42) would not have received a trial of TRT. In conclusion, adoption of the all men age adjusted RR for testosterone has been associated with a significant fall in referrals for investigation of male hypogonadism. However, modelling of historical clinic data would suggest that some non-obese individuals miss out on a therapeutic trial of TRT, especially if the all men, rather than non-obese, age adjusted RR is adopted.
Reference: (1) Travison et al, J Clin Endocrinol Metab, 2017,102(4):1161-1173, (2) Bhasin S et al,. J Clin Endocrinol Metab. March 2018;103(5):1715-1744.</description><subject>Reproductive Endocrinology</subject><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkdtKAzEQhhdRsNS-gFd5gW2TbHazeyOUUg9QVLRehxwmdUublGRb8R18aFO3iF7NP6dvBv4suyZ4TCjBkzU4E_1EHaTErBrXhJ9lA8o4zUnD6fkffZmNYlxjjElTsIaxQfb1Ol3mmHE0NX7Xtd4hb5F0aLqCVFrvYwcGLSF2PqngHaAXsBDA6aSkWx1zs9cQ-3qQm4g6j-bOeB3aND7btK7VCWnQI3yg5wAxNX5OxeOtv-yr7MImAIxOcZi93c6Xs_t88XT3MJsuck0Y5TkQKZXUXEkjiTIVUSVXVpdACNeGl8SqCoy0paJKNhWWoFnZMFqTWhNrq2KY3fTc3V5twWhwXXpc7EK7leFTeNmK_x3XvouVPwhOcV3gMgFoD9DBxxjA_u4SLI6eiN4TcfJEJE-Kb68xhzs</recordid><startdate>20200508</startdate><enddate>20200508</enddate><creator>Dewdney, Charlotte</creator><creator>Mendoza, Heidi</creator><creator>Clark, Rosemary</creator><creator>MacRury, Sandra</creator><creator>Harvey, Rod</creator><creator>Muir, Kenneth</creator><creator>Bal, Satinder</creator><creator>Dorrian, Catherine Anne</creator><creator>Macfarlane, David P</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200508</creationdate><title>SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone</title><author>Dewdney, Charlotte ; Mendoza, Heidi ; Clark, Rosemary ; MacRury, Sandra ; Harvey, Rod ; Muir, Kenneth ; Bal, Satinder ; Dorrian, Catherine Anne ; Macfarlane, David P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1427-e1aabac7bada1bd61b57bfc5e117cd751fb6edaf5b2ba960aec45942818c1ff63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Reproductive Endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dewdney, Charlotte</creatorcontrib><creatorcontrib>Mendoza, Heidi</creatorcontrib><creatorcontrib>Clark, Rosemary</creatorcontrib><creatorcontrib>MacRury, Sandra</creatorcontrib><creatorcontrib>Harvey, Rod</creatorcontrib><creatorcontrib>Muir, Kenneth</creatorcontrib><creatorcontrib>Bal, Satinder</creatorcontrib><creatorcontrib>Dorrian, Catherine Anne</creatorcontrib><creatorcontrib>Macfarlane, David P</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dewdney, Charlotte</au><au>Mendoza, Heidi</au><au>Clark, Rosemary</au><au>MacRury, Sandra</au><au>Harvey, Rod</au><au>Muir, Kenneth</au><au>Bal, Satinder</au><au>Dorrian, Catherine Anne</au><au>Macfarlane, David P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2020-05-08</date><risdate>2020</risdate><volume>4</volume><issue>Supplement_1</issue><issn>2472-1972</issn><eissn>2472-1972</eissn><abstract>Testosterone levels decline with age. However, until recently well defined harmonised age and/or obesity (BMI <30kg/m2) adjusted reference ranges did not exist.1 There is also a lack of international consensus on whether an age adjusted reference range (RR) should be used to define the syndrome of hypogonadism in men. Our local referral guideline suggests referral to endocrinology is appropriate if morning testosterone is <9.4nmol/L similar to the Endocrine Society Clinical Practice Guideline.2 In mid 2018 our laboratory adopted the published all men age adjusted RR1. We sought to; i) investigate clinic referrals before and after adoption of the all men age adjusted RR and, ii) to model the impact on referrals and prescription of testosterone replacement therapy (TRT) had we adopted either the lower limit of either all men or non-obese age adjusted RR as our referral criteria. Despite similar numbers of testosterone levels being measured in the laboratory, referrals to endocrine clinic for investigation of male hypogonadism fell by 52% (n=101 vs 48) in the one year following the introduction of the new age adjusted RR, with a corresponding reduction in prescriptions for testosterone. Mean testosterone concentration (6.7±2.5 vs 6.4±3.9nmol/L [mean±SD], NS), and age (51±13.9 vs 50±17.9 years, NS) of individuals referred were similar before and after the change of RR. Of the 101 patients referred for investigation of hypogonadism prior to the new RR mean testosterone concentrations were 8.5±4.5, 7.3±4.1, 6.8±3.6, 6.7±2.1 & 6.6±1.6nmol/L, with 39, 71, 39, 40 & 17% of the 87 patients seen in clinic being prescribed TRT in age groups 19-39 (n=28), 40-49 (n=7), 50-59 (n=33), 60-69 (n=20) &70-79 (n=6) respectively, excluding those with a history of anabolic steroid use or Klinefelter’s syndrome. Mean BMI was 30.9±4.4kg/m2, which was similar between age groups. Had the lower limit of normal of the all men testosterone RR been employed as our referral criteria in the preceding year, 23.8% (24/101) of referrals would not have met referral criteria, and 26.2% (n=11/42) of those receiving a prescription would potentially not have received a trial of TRT. In contrast, had the non-obese age adjusted RR had been adopted for all men 13.9% (14/101) of referrals would not have met referral criteria and, of those prescribed testosterone, 2.4% (n= 1/42) would not have received a trial of TRT. In conclusion, adoption of the all men age adjusted RR for testosterone has been associated with a significant fall in referrals for investigation of male hypogonadism. However, modelling of historical clinic data would suggest that some non-obese individuals miss out on a therapeutic trial of TRT, especially if the all men, rather than non-obese, age adjusted RR is adopted.
Reference: (1) Travison et al, J Clin Endocrinol Metab, 2017,102(4):1161-1173, (2) Bhasin S et al,. J Clin Endocrinol Metab. March 2018;103(5):1715-1744.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1210/jendso/bvaa046.817</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2472-1972 |
| ispartof | Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1) |
| issn | 2472-1972 2472-1972 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7208305 |
| source | Oxford University Press Open Access; PubMed Central |
| subjects | Reproductive Endocrinology |
| title | SAT-047 Adoption of an Age Adjusted Testosterone Reference Range Reduces Referrals to Endocrine Clinic and New Prescriptions of Testosterone |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A29%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT-047%20Adoption%20of%20an%20Age%20Adjusted%20Testosterone%20Reference%20Range%20Reduces%20Referrals%20to%20Endocrine%20Clinic%20and%20New%20Prescriptions%20of%20Testosterone&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Dewdney,%20Charlotte&rft.date=2020-05-08&rft.volume=4&rft.issue=Supplement_1&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvaa046.817&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_7208305%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1427-e1aabac7bada1bd61b57bfc5e117cd751fb6edaf5b2ba960aec45942818c1ff63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |